Patients with EGFR- or ALK-positive lung-adenocarcinoma showed a trend of better OS compared to those with other histopathologies (MST: 37.2 months vs. 14.6 months, p = 0.077) (Table A2). The gene discussed is EGFR; the disease is lung adenocarcinoma.